Piper Sandler Maintains Neutral on Fulgent Genetics, Lowers Price Target to $21
Benzinga Newsdesk 1 year ago
NewsPrice TargetAnalyst Ratings
Piper Sandler analyst David Westenberg maintains Fulgent Genetics (NASDAQ:FLGT) with a Neutral and lowers the price target from $23 to $21.
Piper Sandler analyst David Westenberg maintains Fulgent Genetics (NASDAQ:FLGT) with a Neutral and lowers the price target from $23 to $21.